Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Top Cited Papers
- 20 May 2004
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 350 (21), 2129-2139
- https://doi.org/10.1056/nejmoa040938
Abstract
Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown. We searched for mutations in the EGFR gene in primary tumors from patients with non–small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib. The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells. Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (PEGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- ErbB-targeted therapeutic approaches in human cancerExperimental Cell Research, 2003
- Epidermal growth factor receptor: mechanisms of activation and signallingExperimental Cell Research, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant PhenotypeScience, 1995
- The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase.Genes & Development, 1994